Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Earns “Outperform” Rating from Wedbush

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)‘s stock had its “outperform” rating restated by research analysts at Wedbush in a report issued on Tuesday, Benzinga reports. They presently have a $40.00 price target on the stock. Wedbush’s target price points to a potential upside of 98.41% from the stock’s current price.

A number of other equities research analysts have also issued reports on DMRA. Guggenheim upped their target price on Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the company a “buy” rating in a research note on Friday. TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a report on Monday, August 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, September 14th. HC Wainwright reiterated a “buy” rating and set a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st. Finally, Jefferies Financial Group assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, July 27th. They set a “buy” rating and a $50.00 price target for the company. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $46.50.

Damora Therapeutics, Inc. Common Stock Stock Performance

DMRA stock traded down $0.59 on Tuesday, reaching $20.16. The company had a trading volume of 64,921 shares, compared to its average volume of 424,343. Damora Therapeutics, Inc. Common Stock has a 1 year low of $3.50 and a 1 year high of $38.33. The company’s fifty day moving average is $28.18 and its 200 day moving average is $26.27. The company has a market cap of $1.24 billion, a P/E ratio of -5.98 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its earnings results on Monday, August 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.06. On average, sell-side analysts predict that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current year.

Insider Buying and Selling at Damora Therapeutics, Inc. Common Stock

In other Damora Therapeutics, Inc. Common Stock news, CEO Jennifer Jarrett purchased 12,500 shares of Damora Therapeutics, Inc. Common Stock stock in a transaction on Friday, September 25th. The shares were bought at an average price of $20.23 per share, with a total value of $252,875.00. Following the purchase, the chief executive officer directly owned 512,500 shares in the company, valued at $10,367,875. This trade represents a 2.50% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in DMRA. Arizona State Retirement System purchased a new position in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth $260,000. Squarepoint Ops LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth $303,000. Seven Fleet Capital Management LP acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth $7,398,000. Finally, Braidwell LP acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth $42,146,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.